OOIR: Observatory of International Research

Papers

(The TQCC of Journal of Clinical Oncology is 1. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)

Article	Citations
Attention to diet, exercise, and weight in the oncology clinic: Results of a national patient survey.	1090
Weight changes according to treatment in a diverse cohort of breast cancer patients.	800
The association of ATM alterations with clinical and molecular features in metastatic castration-resistant prostate cancer.	789
Radiation therapy and associated cardiovascular outcomes in patients with Hodgkin’s lymphoma.	683
The real-world BRCA1/2 germline mutations in Chinese solid tumors.	618
A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS).	553
Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and lung cancer metastasis.	552
Clinical outcomes and prognostic factors in epithelial-myoepithelial carcinoma (EMC) of the breast.	463
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamou	463
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (¹⁷⁷Lu-PSMA-617) use by US urologists and oncologists.	458
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.	458
Health state utility assessment for low-grade glioma.	447
Association of a clinical model based on skeletal muscle radiation attenuation with efficacy for patients with gastric cancer treated with chemotherapy plus PD-1 antibodies: A single-center retrospect	436
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.	419
Prognostic indicators of recurrence after surgical resection in non-pancreatic gastrointestinal neuroendocrine tumors.	400
Deep learning for 4D modeling of glioblastoma multiforme with tumor treating fields (TTFields) therapy.	374
5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non–small cell lung cancer.	374
Portal vein thrombosis in gastrointestinal cancers: Insights into prevalence and prognosis—A nationwide inpatient analysis 2018-2020.	341
Percutaneous cryoablation of breast cancer metastases: Analysis of long-term single center experience, efficacy and outcomes.	339
Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Gender-based prognostic insights—A prospective cohort study.	334
FOLFOX as a therapeutic option in patients with hepatic failure due to liver metastasis of gastrointestinal (GI) system malignancies: A case series.	334
Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.	333
Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.	322
Spectrum of adipokines, batokines, myokines, and growth factors in blood serum of patients with various stages of lung cancer and with immunotherapy with PD-1/PD-L1 inhibitors.	312
Atezolizumab in first-line treatment of metastatic nonsquamous non-small cell lung cancer in the real-world setting.	310

Expression of epidermal growth factor receptor (EGFR) in blood and tumor in patients with breast carcinoma: Prognostic analysis.	305
Comprehensive cancer genomics-based screening of new therapeutic targets and biomarkers for lung cancer.	304
Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.	291
Genetic and treatment risks for diabetes mellitus (DM) in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime (SJLIFE) cohorts.	279
Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.	278
Genome-wide association study to reveal novel germline markers of melanoma survival.	277
Direct targeting of RAS in pancreatic ductal adenocarcinoma with RMC-6236, a first-in-class, RAS-selective, orally bioavailable, tri-complex RAS^MULTI(ON) inhibitor.	271
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.	264
Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.	263
Association of changes of pro-inflammatory markers with physical function in women with breast cancer receiving chemotherapy.	258
Feasibility of a child life specialist program for oncology patients with minor children at home: Qualitative analysis.	257
Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphom	257
Right-censoring bias in trials shared at the Project Data Sphere platform.	255
Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.	254
Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology	253
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.	252
A symptom-adapted physical activity intervention during induction chemotherapy for older adults with acute myeloid leukemia (AML) to maintain physical function.	240
Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational s	238
A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-	237
A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers.	235
Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients	234
Effects of metabolic syndrome on cognitive outcomes in long-term survivors of childhood cancer.	233
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.	232
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analy	231
Treatment-specific risk of second malignancies in five-year survivors of diffuse large B-cell lymphoma.	229
Overall and progression-free survival in young breast cancer patients with low muscle mass and density.	229
Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth facto	227
NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring.	226
Preference-weighted quality of life: Findings from the Selenium and Vitamin E Cancer Prevention Trial (SELECT).	225
A phase Ⅱ, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX	216
Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.	214
Five-day accelerated partial breast irradiation (APBI) using intensity modulated radiation therapy (IMRT) in stage 0-II breast cancer: A report of 214 cases with up to 39 month follow-up.	209
Liquid biopsy for baseline evaluation of tumor burden in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A proof of principle study.	203
An investigation into the impact of next generation sequencing on the use of targeted treatments in glioblastoma.	201
Racial, ethnic, and socioeconomic disparities in diagnosis, treatment, and survival of patients with breast cancer.	201
Descriptive study of the therapeutic aggressiveness in oncology patients in the hospital area of Huelva.	198
Genetic alterations in MSS and TMB-H Chinese colorectal cancer patients.	197
The relationships between cancer diagnosis/prognosis awareness and quality of life, anxiety, and depression in Chinese gastroesophageal cancer patients: A cross-correlation analysis.	196
Association of electronic-health record (EHR)-derived race with BRCA testing in patients (pts) with breast cancer (BC) with similar genetic ancestry (GA) in a clinicogenomic database (CGDB).	196
A national study of allogeneic stem cell transplantation for adults with acute myeloid leukemia: Do gender and age above 70 years matter?	195
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.	194
Feasibility of functional evaluation in older adults with gastroesophageal cancer using fitness trackers.	190
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.	190
Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors.	189
Liver steatosis and fibrosis as independent prognostic factors affecting survival in colorectal cancer with liver metastases.	189
Ground-glass opacity showed response to immunotherapy in cancer patients.	187
Consistency and heterogeneity of microsatellite instability (MSI) status in paired biopsy and surgical specimens of colorectal cancer: A necessity for MSI reassessment after treatment?	186
The role of exosomal LINC00853 in gastric cancer progression.	186
Expression of claudin 18.2 in peritoneal metastasis (PM) of gastric cancer.	186
The power of glycobiology: Precision of polyp detection using glycoproteomic biomarkers.	181

Prognostic impact of local recurrence and timing of palliative radiotherapy in patients with unresectable recurrent rectal cancer.	180
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.	179
Assessing disparities in pancreatic cancer outcomes in African Americans.	177
Characterizing the rare abdominal neoplasms of peritoneum, retroperitoneum, and overlapping sites of peritoneum and retroperitoneum: A review of NCDB database.	175
Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials.	175
Genetic testing of Japanese patients with serrated polyposis syndrome: A multicentric study.	175
A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies.	174
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.	172
Assessing the impact of hypercalcemia of malignancy on clinical outcomes in cancer patients admitted with acute pancreatitis.	172
Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.	171
Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer.	170
Characterization of BCL-2 alternative proteins and outcome in patients with peripheral T-cell lymphoma (PTCL).	168
Identification of TGFBR2 mutation as a negative predictor of immunotherapy in NSCLC.	168
Breast cancer as seen at the Nairobi Hospital.	167
Risks of Organ Preservation in Rectal Cancer: Beyond Distant Metastases, Ultimate Local Failure Can Also Be a Problem	165
Dermatologic diagnoses in oncology patients of color on anticancer therapy: Five-year retrospective review of outpatient dermatology consultations.	165
Evaluating Accuracy of Medical Information Distribution Regarding Risk of COVID-19 Infections and Childhood Cancer Survivors	164
Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns.	164
Prognostic impact of inflammatory profiling during and after multimodal treatment for stage III NSCLC.	164
Cognitive and Adaptive Functioning in Youth With Retinoblastoma: A Longitudinal Investigation Through 10 Years of Age	163
Interactive online skin cancer training game “Whack-a-Mole” assesses training strategies and real-time feedback on melanoma identification among U.S. adults.	163
TMB and BRAF mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.	161
Cellworks Omics Biology Model (CBM) to identify amplifications of chromosome 11p and 1p predict paclitaxel and carboplatin resistance.	159
The timeliness of lung cancer care: A systematic review of systematic/scoping reviews on risk factors and interventions.	159
Overall survival after perioperative chemotherapy in the management of pulmonary metastasis in osteosarcoma.	155
Tumor fraction to improve patient selection for oncology early phase clinical trials: Analysis of two precision medicine studies.	155
Mir-34a as predictor of immunotherapy efficacy in NSCLC patients.	154
Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study.	152
Implementation of a virtual tumor board through VA National TeleOncology service.	152
Efficacy of alpelisib (ALP) + fulvestrant (FUL) with rational use of metformin (MET) in patients with HR+/HER2- advanced breast cancer (ABC).	151
Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.	150
Expanding diversity in colorectal cancer studies with a focus on Hispanic and Latino participant enrollment.	150
Abemaciclib dose escalation to maintain intensity (ADE-MI).	150
Impact on biomarker documentation in community oncology by optimizing clinical decision support.	147
Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach.	147
Factors associated with delays in care of suspicious lung nodules at an academic medical center.	147
Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2.	146
Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports.	144
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).	144
Effects of socioeconomic status (SES) and healthcare resource (HCR) availability on survival in Black patients (pts) versus (vs) White pts with multiple myeloma (MM): A SEER Medicare analysis.	143
Predictors of response and surgical approach after neoadjuvant chemotherapy in receptor-positive/HER2-negative stage II-III breast cancer patients treated in two private cancer care centers in Lima, P	143
Breast cancer outcomes and treatment toxicity in geriatric patients compared to other patients at the Cancer Disease Hospital in Zambia.	141
Disparities in incidence and mortality of hematologic cancers in Southeast Asia: A 2020 analysis.	141
Enrollment of older adults in clinical trials for oncology indications, 2010-2020: An evaluation by the FDA.	140
NSQIP audit of enhanced recovery after surgery protocols for radical cystectomy.	140
Incorporating precision oncology in everyday clinical practice: First two years of comprehensive genomic profiling (CGP) testing experience in Croatia.	139
Financial toxicity (FT), quality of life (QoL), and medication adherence patient-reported outcomes (PROs) in CLL on first-line (1L) oral oncolytics.	139
A novel multi-cancer screening approach based on screening objectives, cancer occurrence mechanism, and cost modeling.	137
A phase I/II trial of neoadjuvant pegylated arginine deiminase (ADI-PEG 20) with ifosfamide and radiotherapy in soft tissue sarcomas (STS) of the trunk or extremity.	136
Commercial health plan spending on oncology drugs approved via the accelerated approval pathway and later withdrawn from the market.	136
Efficacy of mammography screening in women aged 40–49 years: An updated systematic review and meta-analysis.	135
Universal germline testing for cancer susceptibility and actionable noncancer disorders among 19,842 patients: Initial findings from the City of Hope INSPIRE study.	134
Implementation of video assisted point-of-care germline genetic education and testing for patients with peri-diagnostic pancreatic cancer.	134
Safety and efficacy of time restricted eating (TRE) in improving response to immunotherapy in patients with head and neck cancer (HNSCC).	133
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.	130
Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.	130
Effect of IL-15 on anti-tumor immune response to radio-immunotherapy through systemic immune activation.	128
Adherence and perception of the importance of anti-COVID-19 protective measures amongst patients with cancer.	128
PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice.	126
Effect of war on radiotherapy in Ukraine and how to help.	126
Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.	126
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen recep	125
Predictors of long-term survival in immune checkpoint inhibitor (ICI)-associated myocarditis.	125
Stereotactic radiosurgery in patients with small cell lung cancer and 1-10 brain metastases: A multi-institutional, phase II, prospective clinical trial.	125
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen recept	125
The role of folate receptor-positive circulating tumor cells in the prognosis analysis of esophageal squamous cell carcinomas.	125
Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.	124
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.	124
Feasibility of implementing whole genome sequencing into routine oncology care.	124
Real-world impact of KRAS mutations on clinical outcomes in metastatic colorectal cancer treated with trifluridine-tipiracil in the USA.	123
Genomic profile in Mexican women with early-stage breast cancer using Mammaprint+Blueprint assay: A retrospective study.	122
Relationship between immune-inflammatory markers and clinical features and deepness of tumor response and prognosis of patients with PD-L1 ≥50% metastatic NSCLC receiving first-line immunotherapy.	122
COBRA: Assessment of safety and efficacy of ⁶⁴Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.	121
Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy (ALARICE study).	121
Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinic	121
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.	121
Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.	120
A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.	119
VAMANA: A phase 2 study of low-dose bevacizumab plus CCNU in relapsed/recurrent glioblastoma.	119
Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study.	117

Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.	117
Efficacy and safety of combination therapy with envafolimab and lenvatinib in patients with endometrial cancer after failure of first-line platinum-based therapy.	116
Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).	116
A universal pipeline to combine spatial transcriptomics, proteomics, and diagnostic H&E assays on a single tissue section to study tissue microenvironment.	115
Genomic instability is enriched in localized prostate cancers from men of African ancestry.	115
Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience.	115
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.	113
The microbiome landscape of early-onset colorectal cancer: A systematic review.	113
The influence of access to care on radiation therapy utilization among older women with breast cancer.	113
Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer.	113
Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: Data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2.	112
Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis.	112
Use of Oncotype vs. Breast Cancer Index (BCI) for extended endocrine therapy decisions: A single center analysis in stage IA hormone receptor positive breast cancer.	112
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice	112
Use of integrated multi-omics analysis to determine antitumor efficacy of donafenib in combination with FADS2 inhibition in hepatocellular carcinoma.	111
Cardio-Oncology Awareness: A multidisciplinary survey amongst health care trainees and practicing professionals at academic institutions.	110
Evolutionary Dynamics and Intermittent Therapy for Metastatic Cancers	109
Transition of dose-adjusted EPOCH therapy into the outpatient healthcare setting, quality and cost considerations under an alternate payment model.	109
Phase I study of liposomal irinotecan (LY01610) in patients with advanced esophageal squamous cell carcinoma.	108
Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.	108
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metast	107
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).	107
A phase 3 trial of fixed dose combinations of fianlimab (anti–LAG-3) + cemiplimab (anti–PD-1) versus relatlimab + nivolumab in patients with unresectable or metastatic melanoma.	107
PRIMROSE: A modular phase 1/2a study of AZD3470, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP deficient advanced solid tumors.	106
Association of CDX2 expression with clinical, pathologic, and molecular features in MSI-H colorectal cancer.	106
Comparison of real-world mortality data among patients with glioblastoma (GBM) and metastatic pancreatic cancer (mPC) treated in the community oncology setting.	105
A phase I trial of T-cell receptor gene therapy targeting KK-LC-1 for gastric, breast, cervical, lung and other KK-LC-1 positive epithelial cancers.	105
Can immune therapy prevent pre-clinical cancer from progression? The impact of immune therapy on secondary cancer incidence.	105
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms	105
Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.	104
Risk of VTE in TNBC treated with neoadjuvant immunotherapy.	104
Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond Milan criteria: An interim analysis of a multi-	104
Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.	103
Does the time-of-day administration of immune checkpoint inhibitors affect efficacy in patients with metastatic renal cell carcinoma? A single-center study.	103
A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.	101
Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRAS^G12C inhibitor, in advanced solid tumors.	101
Real world experience of bispecific fusion protein in patients with metastatic uveal melanoma: Can we deliver?	101
Oncology-specific Qualified Clinical Data Registry (QCDR) measures to advance cancer care and achieve Merit-Based Incentive Payment System (MIPS) performance.	100
Multiomic characterization to reveal a distinct molecular landscape in young-onset pancreatic cancer.	100
Multicentric retrospective study on the treatment characteristics, efficacy and safety of eribulin in Slovenian patients with breast cancer.	99
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.	99
Underutilization of germline BRCA testing in commercially-insured women diagnosed with ovarian cancer.	99
Interim analysis of a phase II study of simultaneously integrated boost intensity modulated radiation therapy (SIB-IMRT) in combination with 5-FU and mitomycin-C among patients with locally advanced a	98
High incidence of concurrent disease states detected during mobile lung cancer screening in an underserved population.	98
Utility of chemotherapy given before and/or after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for appendiceal adenocarcinoma with peritoneal metastases.	98
Dispersion in total cost of care for Medicare fee-for-service (FFS) patients with metastatic pancreatic cancer receiving FDA-approved/NCCN Category 1 regimens at 340B verus non-340B institutions.	98
Inhibitory effect of lignans from Ailanthus altissima on proliferation of human lung cancer cells and its mechanism.	98
Uptake and effectiveness of checkpoint inhibitor therapy among trial-ineligible patients with advanced solid malignancies.	97
Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatat	97
Efficacy analysis of a remote symptom management platform.	97
Nephrotoxicity in patients with cancer treated with immune checkpoint inhibitors.	96
Analyzing the effects of depression among patients with head and neck cancer.	96
Reducing racial disparities in time to breast cancer diagnosis: Impact of immediate screening mammogram reads during the COVID pandemic.	96
Code status and outcomes in patients with cancer and COVID-19: A COVID-19 and cancer consortium (CCC19) registry analysis.	95
Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR)	95
Impact and predictors of readmission in hypercalcemia of malignancy: Findings of a nationwide analysis.	95
Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC.	94
Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact.	94
Final analysis of a prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC4	93
Quality initiative (QI) to improve molecular testing in newly diagnosed (ND) stage 4 non-small cell lung cancer (NSCLC-4): An Integra Connect (IC) database study.	93
SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors.	93
Modelling treatment benefit for bexmarilimab (an anti-Clever-1 antibody and a novel macrophage checkpoint inhibitor) using phase I first-in-man trial data.	92
Claims-based cardiac monitoring (CM) in patients (Pts) receiving trastuzumab (TZ).	92
An institutional evaluation of the safety and efficacy of same-day administration of pegfilgrastim in patients receiving chemotherapy for lung cancer.	92
Predictors of electronic health record (EHR) portal registration and frequency of portal use among patients with cancer prior to engagement in the IMPACT Consortium symptom management trials.	92
Irradiated esophageal squamous cell carcinoma cells induced the increase of Treg by TGF-beta.	92
A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.	92
The concerning disaggregation of gender disparity and racial disparity investigation at recent ASCO annual meetings.	92
A pilot intervention to improve health insurance literacy and financial toxicity among recently diagnosed adolescents and young adults with cancer.	91
Variation in the use of genomic testing in patients with metastatic colorectal cancer.	91
Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.	91
Association between timely targeted therapy initiation and clinical outcomes in patients with advanced HER2+ gastroesophageal adenocarcinoma.	91
Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus c	91
Real-world BRAF testing patterns for patients with metastatic colorectal cancer (mCRC), metastatic melanoma, and non-small cell lung cancer (NSCLC).	90
Circulating tumor DNA mutation as a prognostic marker in melanoma with brain metastasis.	89
KRAS mutation detection and cfDNA in liquid biopsy as prognostic factors in pancreatic adenocarcinoma.	89
Real-world clinical practice: Toxicities of maintenance PARP inhibitors in recurrent ovarian cancer—The Royal Marsden experience.	89
LUNG cancer: Supportive oncology program development for patients and care partners: A qualitative study.	88
Preliminary clinical investigations of high-dose furmonertinib in NSCLC with EGFR Exon 20 insertions (20ins).	88
Glypican-3-specific CAR-NKT cells overexpressing BATF3 mediate potent antitumor activity against hepatocellular carcinoma.	88
A mixed-methods study of healthcare provider perspectives on the barriers to enrollment of minority patients on cancer clinical trials.	87
A phase II study of anlotinib and an anti-PDL1 antibody in patients with alveolar soft part sarcoma: Results of expansion cohorts.	87
Global retrospective study comparing consolidation ALK tyrosine kinase inhibitors (TKI) to durvalumab (durva) or observation (obs) after chemoradiation (CRT) in unresectable locally-advanced ALK+ non-	87
EGRET: A first-in-human study of the novel antibody-drug conjugate (ADC) AZD9592 as monotherapy or combined with other anticancer agents in patients (pts) with advanced solid tumors.	87
A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.	87
Cross-ancestry polygenic risk score for breast cancer risk assessment.	86
Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS.	86
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.	85
Validation of National Comprehensive Cancer Network Guidelines (NCCN) at a single institution.	85
Case series on the safety of mRNA COVID19 vaccines in cancer patients undergoing treatment.	85
An observational study of best supportive care with or without oral capecitabine in patients with metastatic gallbladder cancer.	84
Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).	84
Adult BMI change over time and risk of colorectal adenoma.	84
Quality of educational YouTube videos related to pancreatic cancer: Analysis of patient-focused and NCI-designated cancer center videos.	84
Improvement of a clinical colorectal cancer risk prediction model integrating polygenic risk.	84